- This event has passed.
Putting Your Best Foot Forward
September 9 @ 1:00 pm - 2:00 pm UTC-7
Life science startups need strong partnerships to thrive. Making a meaningful connection to a pharma partner or key investor at the right time can be the difference between a fast track to growth or languishing in the lab. These partnerships bring not only much-needed capital, but also invaluable introductions and industry insights.
We are excited to offer this special program led by Jim Greenwood, former CEO of BIO and now Senior Policy Advisor at DLA Piper, who will help companies understand what VCs and strategic alliance partners are looking for as they evaluate startups and founding teams. Joining him will be Laura Stoppel, Principal at RA Capital Management, a leading life sciences venture capital fund; and Jason Hafler, Managing Director, Sanofi Ventures, representing a corporate venture group.
The discussion will cover the importance of modifying your elevator pitch to align with the interest of your audience, the need to invest time in researching partners and building relationships, and some pro tips on what to do to make a good first impression. The program is designed for early stage life science companies planning to raise capital or pursue an alliance with a pharma partner in the next 12-18 months.
Jim Greenwood, former CEO of BIO and now Senior Policy Advisor at DLA Piper
Prior to joining DLA Piper, Jim served as president and CEO of BIO, a trade association that represents 1,000 biotechnology companies, academic institutions and state biotechnology centers across the US and in more than 30 countries. Its members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the annual BIO International Convention, as well as other major investor and business conferences across the world.
Laura Stoppel, Principal at RA Capital Management
Laura Stoppel is a Principal on the Investment Team at RA Capital Management. Laura works on both public and private investments and serves as a Board Director for Artiva Biotherapeutics, Nimbus Therapeutics, and Acumen Pharmaceuticals. Previously, Laura covered hematologic malignancies, cell therapies, retinal diseases, and orphan neurodevelopmental disorders. Laura holds a BA in Biology and Psychology from Harvard University, and a PhD in Neuroscience from MIT. Her graduate research investigated synaptic translation in syndromic autism.
Jason Hafler, Managing Director, Sanofi Ventures
Jason currently serves as the Managing Director of Sanofi Ventures. Prior to Sanofi, Jason was the Director of Corporate Development at Translate Bio (fka RaNA Therapeutics), a company co-founded by his previous firm Atlas Venture. While at Atlas, Jason was an Associate in the Life Sciences group. Previously, he was a Flagship Ventures Entrepreneurial Fellow, and consulted for the technology transfer company at the University of Cambridge while performing his doctoral research. Before his time at Cambridge, Jason was an analyst at JSB Partners LP, an investment banking firm, focusing on advisory and business development activities in the life sciences space. Jason graduated with honors from Bowdoin College, and holds a Ph.D. from the University of Cambridge